Development, Characterization and Evaluation of Lactoferrin Conjugated and Memantine Loaded Peg-Plga Nanoparticles for the Treatment of Alzheimer's Disease
Rashi Jain *
School of Pharmacy, LNCT University Bhopal, M.P., India.
Virendra K. Sharma
School of Pharmacy, LNCT University Bhopal, M.P., India.
*Author to whom correspondence should be addressed.
Abstract
Alzheimer's disease is a degenerative neurological condition that has no cure and only a few treatment options. It has a negative impact on one's cognitive and behavioural abilities. Traditional medications, such as acetylcholinesterase inhibitors, are often ineffective because they do not penetrate the blood-brain barrier. Targeted therapy strategies involving nanoparticulate drug delivery devices have been employed to improve the efficacy of Alzheimer's disease treatment. Memantine is an Alzheimer's disease medicine that has been approved for the treatment of mild to moderate symptoms. To boost memantine's action at the target region, we employed a twofold emulsion technique to generate lactoferrin (Lf) combined with biodegradable PEG-PLGA nanoparticles (NPs). The average particle size of the synthesised NPs was 162.60.5 nm, with a polydispersity index of 0.1 and a surface charge of -21.5 mV. The crystalline drug was disseminated within the PLGA matrix, according to the physicochemical characterisation of NPs. During in vitro dissolution studies, the new nanoparticulate formulation displayed a sustained release profile of memantine. The NPs were noncytotoxic to brain cell lines, and bEnd.3 cells had a greater concentration of Lf-NP than unconjugated nanoparticles. The researchers discovered that Lf-conjugated PEG-PLGA nanoparticles carrying memantine are excellent for Alzheimer's disease targeted delivery.
Keywords: Alzheimer's disease, bEnd.3, lactoferrin, memantine, PLGA nanoparticles, PEG